APPLICATION AID
    1.
    发明申请
    APPLICATION AID 有权
    申请援助

    公开(公告)号:US20140155845A1

    公开(公告)日:2014-06-05

    申请号:US14236415

    申请日:2012-08-03

    IPC分类号: A61K9/70 A61M35/00

    摘要: The invention relates to a transdermal therapeutic system (10) comprising an active ingredient depot (11) that contains at least one active ingredient, comprising an application face which is designed for applying on a skin and which is adhesive on at least some parts of the surface, and comprising a protective film (14) which covers the application face and which comprises a first protective film part (14a) and a second protective film part (14b). The first protective film part (14a) differs from the second protective film part (14b) in terms of physical properties.

    摘要翻译: 本发明涉及一种透皮治疗系统(10),其包含含有至少一种活性成分的活性成分贮库(11),其包含施用面,所述施用面被设计用于施用于皮肤上,并且所述施用面在所述至少一部分 并且包括覆盖所述涂布面的保护膜(14),所述保护膜包括第一保护膜部分(14a)和第二保护膜部分(14b)。 第一保护膜部分(14a)与第二保护膜部分(14b)的物理性质不同。

    Transdermal Therapeutic System for Administering an Active Substance
    2.
    发明申请
    Transdermal Therapeutic System for Administering an Active Substance 审中-公开
    用于管理活性物质的透皮治疗系统

    公开(公告)号:US20140323996A1

    公开(公告)日:2014-10-30

    申请号:US13994242

    申请日:2011-12-14

    IPC分类号: A61K9/70 A61K31/27

    摘要: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, said system being suitable for an application period of at least three days, comprising the layers arranged in the following order with respect to each other: a) a cover layer, b) an active substance layer comprising a polymer matrix containing the active substance, c) an adhesive layer comprising a contact adhesive, which consists of a mixture of one or more polyisobutylenes and one or more polybutenes, and d) a pull-off layer.

    摘要翻译: 本发明涉及一种用于通过皮肤施用活性物质的透皮治疗系统,所述系统适用于至少三天的施用期,其包括以下列顺序相对于彼此排列的层:a)盖 层,b)包含含有活性物质的聚合物基质的活性物质层,c)包含由一种或多种聚异丁烯和一种或多种聚丁烯的混合物组成的接触粘合剂的粘合剂层,以及d)拉脱 层。

    Application aid
    3.
    发明授权
    Application aid 有权
    申请援助

    公开(公告)号:US09439873B2

    公开(公告)日:2016-09-13

    申请号:US14236415

    申请日:2012-08-03

    摘要: The invention relates to a transdermal therapeutic system (10) comprising an active ingredient depot (11) that contains at least one active ingredient, comprising an application face which is designed for applying on a skin and which is adhesive on at least some parts of the surface, and comprising a protective film (14) which covers the application face and which comprises a first protective film part (14a) and a second protective film part (14b). The first protective film part (14a) differs from the second protective film part (14b) in terms of physical properties.

    摘要翻译: 本发明涉及一种透皮治疗系统(10),其包含含有至少一种活性成分的活性成分贮库(11),其包含施用面,所述施用面被设计用于施用于皮肤上,并且所述施用面在所述至少一部分 并且包括覆盖所述涂布面的保护膜(14),所述保护膜包括第一保护膜部分(14a)和第二保护膜部分(14b)。 第一保护膜部分(14a)与第二保护膜部分(14b)的物理性质不同。

    Transdermal therapeutic system for administering rivastigmine or derivatives thereof
    4.
    发明授权
    Transdermal therapeutic system for administering rivastigmine or derivatives thereof 有权
    用于施用利凡斯的明或其衍生物的透皮治疗系统

    公开(公告)号:US08962014B2

    公开(公告)日:2015-02-24

    申请号:US13518006

    申请日:2010-12-14

    IPC分类号: A61F13/00 A61K9/70 A61K31/27

    摘要: The present invention relates to a transdermal therapeutic system for administering an active substance through the skin, comprising: a) a cover layer, b) a reservoir present on the cover layer, comprising a polymer matrix comprising the active substance, c) an adhesive layer present on the reservoir comprising a contact adhesive, and d) a removable layer present on the adhesive layer, the active substance being rivastigmine, a physiologically compatible salt, hydrate, solvate or derivative thereof, characterized in that the polymer matrix of the reservoir comprises neither hydroxyl groups nor carboxyl groups.

    摘要翻译: 本发明涉及一种用于通过皮肤施用活性物质的透皮治疗系统,包括:a)覆盖层,b)存在于覆盖层上的储存器,其包含含有活性物质的聚合物基质,c)粘合剂层 存在于包含接触粘合剂的储存器上,以及d)存在于粘合剂层上的可除去层,活性物质为利伐斯的明,生理上相容的盐,水合物,溶剂合物或衍生物,其特征在于,所述储存器的聚合物基质既不包含 羟基也不是羧基。

    TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO-PHASE RELEASE PROFILE
    5.
    发明申请
    TRANSDERMAL THERAPEUTIC SYSTEM WITH TWO-PHASE RELEASE PROFILE 审中-公开
    具有两相释放特性的超导治疗系统

    公开(公告)号:US20100143475A1

    公开(公告)日:2010-06-10

    申请号:US12311305

    申请日:2007-08-27

    CPC分类号: A61K9/7061 A61K31/48

    摘要: The present invention relates to a transdermal therapeutic system (TTS) consisting of an impermeable coating, a matrix containing an ergoline compound having the formula (I) or a physiologically compatible salt or derivative thereof, wherein R1 denotes an H atom or a halogen atom and R2 is an alkyl group having 1 to 4 carbon atoms and denotes a single or double bond, and a removable protective layer, wherein the ergoline compound or a physiologically compatible salt or derivative thereof is stabilised by an antioxidant and a basic polymer. The TTS is characterised in that the matrix contains at least one hydrocarbon having 8 to 18 carbon atoms in a straight or branched chain, which has a functional group at the end of the alkyl chain and/or Aloe Vera, so that in a first phase (0-5 hours after application) only 0-20% of the therapeutically desired steady-state plasma concentration of the ergoline compound is achieved and the therapeutically desired steady-state plasma concentration of the ergoline compound is only achieved in a second phase (5-20 hours after application).

    摘要翻译: 本发明涉及一种由不透水涂层组成的透皮治疗系统(TTS),含有式(I)的麦角灵化合物或其生理上相容的盐或衍生物的基质,其中R1表示H原子或卤素原子, R2是具有1至4个碳原子并且表示单键或双键的烷基和可除去的保护层,其中麦角灵化合物或其生理上相容的盐或其衍生物由抗氧化剂和碱性聚合物稳定。 TTS的特征在于,基质含有至少一个在直链或支链上具有8至18个碳原子的烃,其在烷基链和/或芦荟末端具有官能团,因此在第一相中 (施用后0-5小时)仅实现治疗期望的稳态血浆浓度的0〜20%的麦角灵化合物,并且仅在第二阶段(5)中实现麦角灵化合物的治疗期望的稳态血浆浓度 应用后-20小时)。